Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.02, $0.51 better than the analyst estimate of $1.51. Revenue for the quarter came in at $7.54 billion versus the consensus estimate of $7.01 billion.

GUIDANCE:

Gilead Sciences sees FY2024 EPS of $4.25-$4.45, versus the consensus of $3.81.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.